Still, the results don't necessarily spell the end for Dimebon. Pfizer is continuing three studies that could prove Dimebon helps patients in combination with other Alzheimer's drugs or when used for a longer period.
2) Meanwhile, Pfizer is reportedly gearing up this week to bid 3 million euro ($4.08 billion) for Ratiopharm, a generic drug maker based in Germany, according to Bloomberg News, which cited two unidentified people with knowledge of the talks.
What’s the trade?
Pfizer is all about Lipitor, says Mike Huckman, it’s the best selling drug in history and it goes generic next year. Pfizer needs something to fill that gaping hole.
That suggests it will need to make other acquisitions, he adds. I’d suggest putting Vertex, Dendreon, and Human Genome on the radar.
THE NEXT TAKEOUT
Considering the flurry of M&A chatter, who’s next?
Potential Takeover Target Sector
Bristow Group Energy
Hormel Foods Cons. Staples
Green Mountain Coffee Cons. Staples
Watson Pharmaceuticals Health care
Autozone Cons. Discretionary
Source: Brian Belski, Oppenheimer
If you're looking for a takeover target, I'd keep OSI on the radar, counsels Jon Najarian. I think we could see multiple offers.
I love the gold market for takeovers, counsels Brian Kelly, especially the junior miners.
SECTOR TRADE: COMMERCIAL GROWTH
You've been hearing it for months: commercial real estate is the next shoe to drop. But you wouldn't know it by the M&A frenzy taking hold of the sector this week.
What’s the trade?
TECH: NO DEAL
We’re seeing deal making in pharma, and deal making in commercial real estate. Yet in one of the most cash-rich sectors -- tech -- no deals!
What’s wrong with the picture?
---------------(scroll down for more trades)---------------
Got something to to say? Send us an e-mail at firstname.lastname@example.org and your comment might be posted on the Rapid Recap. If you'd prefer to make a comment but not have it published on our website send those e-mails to email@example.com.
CNBC.com with wires